Eye Meds Now

 Quick Ophthalmic Drug Search

231 items found
LORATADINE CHILDREN'S (loratadine (10 mg) chewables; (5 mg/5 mL) oral solution)
Over the Counter
Oral
Chewable Tablets
Oral Solution
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Runny nose; sneezing; itchy watery eyes; itching of the nose or throat:

  • Chewable tablets:
    • Adults and children 6 years of age:
      • Chew 2 tablets daily.
      • Do not take more than 2 tablets in 24 hours.
    • Children 2 to 6 years of age:
      • Chew 1 tablet daily.
      • Do not take more than 1 tablet in 24 hours.
    • Children < 2 years of age:
      • Ask a doctor.
    • Individuals who have liver or kidney disease:
      • Ask a doctor.
  • Oral solution:
    • Adults and children 6 years of age:
      • 10 mL (10 mg) daily.
      • Do not take more than 10 mL (10 mg) in 24 hours.
    • Children 2 to 6 years of age:
      • 5 mL (5 mg) daily.
      • Do not take more than 5 mL (5 mg) in 24 hours.
    • Children < 2 years of age:
      • Ask a doctor.
    • Individuals who have liver or kidney disease:
      • Ask a doctor.

How Supplied:  
  • Chewables:
    • 5 mg chewables
  • Oral solution:
    • 5 mg/5 mL solution

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


LOTEMAX (loteprednol etabonate (0.5%) ophthalmic gel; (0.5%) ophthalmic ointment; (0.5%) ophthalmic suspension)
Prescription
Topical
Gel
Ointment
Ophthalmic Suspension
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of post-operative inflammation and pain following ocular surgery.

LOTEMAX suspension is also indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.

Consult package insert for additional information.

This medication has a broad FDA approval for "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Post-operative inflammation and pain following ocular surgery:

  • Ophthalmic gel:
    • Invert closed bottle and shake once to fill tip before instilling drops.
    • Apply 1 – 2 drops into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period. 
  • Ophthalmic ointment:
    • Apply a small amount (approximately ½ inch ribbon) into the conjunctival sac(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.
  • Ophthalmic suspension:
    • Shake vigorously before using.
    • Instill 1 – 2 drops into the conjunctival sac of the operated eye(s) 4 times daily, beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.

​​​​​​Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe and post-operative inflammation:

  • Ophthalmic suspension:
    • Shake vigorously before using.
    • Steroid responsive disease:
      • Instill 1 – 2 drops into the conjunctival sac of the affected eye(s) 4 times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary.
      • Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after 2 days the patient should be re-evaluated.

Recurrent corneal erosion:

  • Ophthalmic suspension:
    • Shake vigorously before using.
    • Instill 1 drop in the affected eye 2 – 4 times/day for 2 – 4 weeks.
Recurrent corneal erosion typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Ophthalmic gel:
    • 5 g bottles
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic suspension:
    • 5 mL bottles
    • 10 mL bottles
    • 15 mL bottles

Preservatives:  

benzalkonium chloride (ophthalmic gel, ophthalmic suspension); none listed in package insert (ophthalmic ointment).


Storage:  
  • Store upright at 59° – 77°F (15° – 25°C).
  • Do not freeze.
  • Use gel only if imprinted neckband is intact.
  • Do not use ointment if tamper evident skirt is visible on bottom of cap.
  • Do not use suspension if neckband imprinted with "Protective Seal" and yellow (mortar and pestle graphic) is not intact.


Assistance: Payment Assistance

LOTEMAX SM (loteprednol etabonate (0.38%) ophthalmic gel)
Prescription
Topical
Gel
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of post-operative inflammation and pain following ocular surgery.


Typical Dosing:  

►Post-operative inflammation and pain following ocular surgery:

  • Invert closed bottle and shake once to fill tip before instilling drops.
  • Apply 1 drop into the conjunctival sac of the affected eye three times daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period.

Recurrent corneal erosion:

  • Invert closed bottle and shake once to fill tip before instilling drops.
  • Instill 1 drop in the affected eye 2 – 4 times/day for 2 – 4 weeks.
Recurrent corneal erosion typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 5 g bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store upright at 59° – 77°F (15° – 25°C).
  • Can be used until the expiration date on the bottle after opening.


Assistance: Payment Assistance

LUCENTIS (ranibizumab (0.3 mg/0.05 mL; 0.5 mg/0.5 mL) injection)
Prescription
Injectable
Intravitreal
VEGF Inhibitors
Indications/Usage:

Indicated for the treatment of patients with: neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy; myopic choroidal neovascularization.


Typical Dosing:  

►General dosing information:

  • FOR OPHTHALMIC INTRAVITREAL INJECTION.
  • Vials: A 5-micron sterile filter needle (19-gauge x 1½ inch), a 1 mL Luer lock syringe and a 30-gauge x ½ inch sterile injection needle are needed but not included.

►Neovascular (wet) age-related macular degeneration (AMD):

  • 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
  • Although not as effective,  patients may be treated with 3 monthly doses, followed by less frequent dosing with regular assessment. In the 9 months after three initial monthly doses, less frequent dosing with 4 – 5 doses on average is expected to maintain visual acuity while monthly dosing may be expected to result in an additional average 1 – 2 letter gain. Patients should be assessed regularly [See Clinical Studies (14.1) in package insert].
  • Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average. Patients should be assessed regularly [See Clinical Studies (14.1) in package insert].

►Macular edema following retinal vein occlusion (RVO):

  • 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
  • Consult package insert for additional information.

►Diabetic macular edema (DME) and diabetic retinopathy (DR):

  • 0.3 mg (0.05 mL of 6 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

►Myopic choroidal neovascularization (mCNV):

  • 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to 3 months. Patients may be retreated if needed [See Clinical Studies (14.5) in package insert].

Additional information for Dosage and Administration is in Notes below.


How Supplied:  
  • Prefilled syringes, single-use:
    • 0.3 mg/0.05 mL prefilled syringe (0.05 mL)
    • 0.5 mg/0.05 mL prefilled syringe (0.05 mL)
  • Vials, single-use:
    • 0.3 mg/0.05 mL vial (0.05 mL)
    • 0.5 mg/0.05 mL vial (0.05 mL)

Preservatives:  

None listed in package insert.


Storage:  
  • EACH CARTON IS FOR SINGLE-EYE USE ONLY.
  • Should be refrigerated at 36° – 46°F (2° – 8°C).
  • DO NOT FREEZE.
  • Do not use beyond the date stamped on the label.
  • Protect prefilled syringe and vials from light and store in the original carton until time of use.
  • Do not open prefilled syringe sealed tray until time of use.


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

LUMIFY (brimonidine tartrate (0.025%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Ocular Decongestants/Vasoconstrictors
Indications/Usage:

Used to relieve redness of the eye due to minor eye irritations.


Typical Dosing:  

►Redness of the eye due to minor eye irritations:

  • Adults and children 5 years of age:
    • Instill 1 drop in the affected eye(s) every 6 – 8 hours.
    • Do not use more than 4 times daily.
    • Remove contact lenses before use.
    • Wait at least 10 minutes before re-inserting contact lenses after use.
    • If using other ophthalmic products while using this product, wait at least 5 minutes between each product.
    • To avoid contamination, do not touch tip of container to any surface.
    • Replace cap after each use.
  • Children < 5 years of age:
    • Consult a doctor.

How Supplied:  
  • 7.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


LUMIGAN (bimatoprost (0.01%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intracocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intracocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended: 

  • Instill 1 drop into the affected eye(s) once daily in the evening. 
  • Should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect.
  • Reduction of the IOP starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 – 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles
  • 7.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


Assistance: Payment Assistance

MACUGEN (pegaptanib (0.3 mg) intravitreal solution)
Prescription
Injectable
Intravitreal
VEGF Inhibitors
Indications/Usage:

Indicated for the treatment of neovascular (wet) age-related macular degeneration.


Typical Dosing:  

►Neovascular (wet) age-related macular degeneration:

  • FOR OPHTHALMIC INTRAVITREAL INJECTION ONLY.
  • 0.3 mg should be administered once every 6 weeks by intravitreous injection into the eye to be treated.
  • Additional information for Preparation for Administration and Administration is in Notes below.

How Supplied:  
  • 0.3 mg prefilled syringes (0.09 mL)

Preservatives:  

None listed in package insert.


Storage:  
  • Store in the refrigerator at 36° – 46°F (2° – 8°C).
  • Do not freeze or shake vigorously.
  • Rx only.


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

MAXIDEX (dexamethasone (0.1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal bums, or penetration of foreign bodies.

This medication has a broad FDA approval for "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies:

  • SHAKE WELL BEFORE USING.
  • Instill 1 – 2 drops topically in the conjunctival sac.
  • In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides.
  • In mild disease, drops may be used up to 4 – 6 times daily.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store upright at 46° – 80°F (8° – 27°C).


Assistance: Payment Assistance

MAXITROL (neomycin sulfate (3.5 mg/g) – polymyxin B sulfate (10,000 units/g) – dexamethasone (0.1%) ophthalmic ointment; ophthalmic suspension)
Prescription
Topical
Ointment
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.

Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus; Escherichia coli; Haemophilus influenzae; Klebsiella/Enterobacterspecies; Neisseria species; Pseudomonas aeruginosa.

This product does not provide adequate coverage against: Serratia marcescens and streptococci, including Streptococcus pneumoniae.

This medication has a broad FDA approval for "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Steroid-responsive inflammatory ocular conditions:

  • Ophthalmic ointment:
    • Apply a small amount into the conjunctival sac(s) up to 3 – 4 times daily.
    • How to apply:
      • Tilt your head back.
      • Place a finger on your cheek just under your eye and gently pull down until a "V" pocket is formed between your eyeball and your lower lid.
      • Place a small amount (about ½ inch) in the "V" pocket. Do not let the tip of the tube touch your eye.
      • Look downward before closing your eye.
    • Not more than 8 g should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.
  • Ophthalmic suspension:
    • Instill 1 – 2 drops in the conjunctival sac(s).
    • In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. In mild disease, drops may be used up to 4 – 6 times daily.
    • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic suspension:
    • 5 mL bottles

Preservatives:  

methylparaben and propylparaben (ophthalmic ointment); benzalkonium chloride (ophthalmic suspension)


Storage:  
  • Store ophthalmic ointment at 36° – 77°F (2° – 25°C).
  • Store ophthalmic suspension upright at 46° – 80°F (8° – 27°C).


METHAZOLAMIDE (methazolamide (25 mg; 50 mg) tablets)
Prescription
Oral
Tablets
Carbonic Anhydrase Inhibitors
Indications/Usage:

Indicated in the treatment of ocular conditions where lowering intraocular pressure (IOP) is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and pre-operatively in acute angle-closure glaucoma where lowering the IOP is desired before surgery.


Typical Dosing:  

►Ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit:

  • The effective therapeutic dose varies from 50 mg – 100 mg, 2 – 3 times daily:
  • The drug may be used concomitantly with miotic and osmotic agents.

How Supplied:  
  • 25 mg tablets
  • 50 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Store in a tight, light-resistant container.


METHYLPREDNISOLONE (methylprednisolone (4 mg; 8 mg; 16 mg; 32 mg) tablets)
Prescription
Oral
Tablets
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated in the following ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers; herpes zoster ophthalmicus; anterior segment inflammation; diffuse posterior uveitis and choroiditis; sympathetic ophthalmia; keratitis; optic neuritis; allergic conjunctivitis; chorioretinitis; iritis and iridocyclitis.

This medication has a broad FDA approval for "severe chronic allergic and inflammatory processes involving the eye and its adnexa." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "severe chronic allergic and inflammatory processes involving the eye and its adnexa." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers; herpes zoster ophthalmicus; anterior segment inflammation; anterior diffuse posterior uveitis and choroiditis; sympathetic ophthalmia; keratitis; optic neuritis; allergic conjunctivitis; chorioretinitis; iritis and iridocyclitis:

  • The initial dosage may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Methylprednisolone should be discontinued and the patient transferred to other appropriate therapy.
  • IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of Methylprednisolone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
  • Tapered dosage schedule (4 mg tablets):
    • 1st day:
      • Take 2 tablets before breakfast, 1 tablet after lunch and supper, and 2 tablets at bedtime.
      • Unless otherwise directed by your physician, all 6 tablets in the row labeled 1st day should be taken the day you receive your prescription, even though you may not receive it until late in the day. All 6 tablets may be taken immediately as a single dose, or may be divided into 2 or 3 doses and taken at intervals between the time you receive the medicine and your regular bedtime.
    • 2nd day:
      • Take 1 tablet before breakfast, 1 tablet after lunch and supper, and 2 tablets at bedtime.
    • 3rd day:
      • Take 1 tablet before breakfast and 1 tablet after lunch, after supper, and at bedtime.
    • 4th day:
      • Take 1 tablet before breakfast, after lunch, and at bedtime.
    • 5th day:
      • Take 1 tablet before breakfast and at bedtime.
    • 6th day:
      • Take 1 tablet before breakfast.
  • Consult package insert for additional information.

How Supplied:  
  • 4 mg tablets
  • 8 mg tablets
  • 16 mg tablets
  • 32 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68 – 77° F (20 – 25°C).


MINOCIN (minocycline hydrochloride (50 mg; 75 mg; 100 mg) capsules)
Prescription
Oral
Capsules
Antibiotics
Indications/Usage:

Indicated in the treatment of the following infections due to susceptible strains of the designated microorganism: trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence; inclusion conjunctivitis caused by Chlamydia trachomatis.

Designated gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

  • Escherichia coli.
  • Enterobacter aerogenes.
  • Shigella species.
  • Acinetobacter species.

Designated gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

  • Skin and skin structure infections caused by Staphylococcus aureus. (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.)

Consult package insert for additional information.

This medication has a broad FDA approval for "infections due to susceptible strains of the designated microorganisms." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "infections due to susceptible strains of the designated microorganisms." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Infections due to susceptible strains of listed microorganisms:

  • Pediatric patients > 8 years of age, usual dose:
    • 4 mg/kg initially followed by 2 mg/kg every 12 hours, not to exceed the usual adult dose.
  • Adults, usual dose:
    • 200 mg initially followed by 100 mg every 12 hours. Alternatively, if more frequent doses are preferred, two or four (50 mg) pellet-filled capsules may be given initially followed by one (50 mg) capsule 4 times daily.
  • THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF MINOCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.
  • MINOCIN Pellet-Filled Capsules may be taken with or without food (See CLINICAL PHARMACOLOGY in package insert).
  • Ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline-class is recommended to reduce the risk of esophageal irritation and ulceration. The pellet-filled capsules should be swallowed whole.
  • The pharmacokinetics of minocycline in patients with renal impairment (CrCl < 80 mL/min) have not been fully characterized. Current data are insufficient to determine if a dosage adjustment is warranted. The total daily dosage should not exceed 200 mg in 24 hours. However, due to the antianabolic effect of tetracyclines, BUN and creatinine should be monitored (See WARNINGS in package insert).

►Ocular rosacea:

  • 50 – 100 mg orally 2 times daily for 1 month or longer.

►Inclusion (chlamydial) conjunctivitis:

  • 100 mg orally 2 times daily.
Dosing for ocular rosacea and inclusion (chlamydial) conjunctivitis is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 50 mg capsules
  • 75 mg capsules
  • 100 mg capsules

Preservatives:  

None listed in package insert.


Storage:  
  • Store at controlled room temperature, 68°– 77°F (20°– 25°C).
  • Protect from light, moisture and excessive heat.
  • Store in a tight, light-resistant container.


MIOCHOL-E (acetylcholine chloride (20 mg/2 mL) intraocular solution)
Prescription
Injectable
Intraocular
Miotics
Indications/Usage:

Indicated to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required.


Typical Dosing:  

►Miosis of the iris:

  • Instill into the anterior chamber before or after securing one or more sutures.
  • Instillation should be gentle and parallel to the iris face and tangential to pupil border.
  • If there are no mechanical hindrances, the pupil starts to constrict in seconds and the peripheral iris is drawn away from the angle of the anterior chamber. Any anatomical hindrance to miosis must be released to permit the desired effect of the drug.
  • In most cases, 0.5 to 2 mL produces satisfactory miosis. Note that the syringe filter supplied with Miochol-E has a priming volume of 0.6 mL (approximately).
  • In cataract surgery, use Miochol-E only after delivery of the lens.
  • Aqueous solutions of acetylcholine chloride are unstable:
    • Prepare solution immediately before use.
    • Do not use solution that is not clear and colorless.
    • Discard any solution that has not been used.
  • Additional information for Preparation for Administration is in Notes below.

How Supplied:  
  • 20 mg blister packs, each containing:
    • One 0.2 micron sterile filter
    • Ampule of 2 mL diluent
    • Vial of 20 mg acetylcholine chloride powder for intraocular solution

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 39° – 77°F (4° – 25°C).
  • KEEP FROM FREEZING.
  • KEEP OUT OF REACH OF CHILDREN.


MIOSTAT (carbachol (0.01%) intraocular solution)
Prescription
Injectable
Intraocular
Miotics
Indications/Usage:

Indicated for intraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure (IOP) elevation in the first 24 hours after cataract surgery.


Typical Dosing:  

►Intraocular use for obtaining miosis during surgery or reducing the intensity of intraocular pressure (IOP) elevation in the first 24 hours after cataract surgery:

  • Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation.
  • No more than 0.5 milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures.
  • Miosis is usually maximal within 2 to 5 minutes after application.

How Supplied:  
  • 1.5 mL vials

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 86°F (15° – 30°C).


MITOSOL (mytomycin (0.2 mg) kit for ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Other Medications
Indications/Usage:

Indicated for use as an adjunct to ab externo glaucoma surgery.


Typical Dosing:  

►Adjunct to ab externo glaucoma surgery:

  • For topical application to the surgical site of glaucoma filtration surgery. Not intended for intraocular administration. If intraocular administration occurs, cell death leading to corneal infarction, retinal infarction, and ciliary body atrophy may result.
  • Reconstitution: Each vial contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. To reconstitute, add 1 mL of sterile water for Injection, then shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until the product dissolves into solution.
  • Method of use: Sponges provided within the Mitosol® Kit should be fully saturated with the entire reconstituted contents in the manner prescribed in the Instructions for Use. A treatment area approximating 10 mm x 6 mm +/- 2 mm should be treated with the Mitosol®. Apply fully saturated sponges equally to the treatment area, in a single layer, with the use of a surgical forceps. Keep the sponges on the treatment area for 2 minutes, then remove and return to the Mitosol® Tray for defined disposal in the Chemotherapy Waste Bag provided.
  • Additional information on Stability is in Notes below.

How Supplied:  
  • 0.2 mg kits

Preservatives:  

None listed in package insert.


Storage:  
  • Store kits at 68° – 77°F (20° – 25°C). 
  • Avoid excessive heat.
  • Protect from light.
  • Procedures for Proper Handling and Disposal of anti-cancer drugs should be followed. Appropriate containment and disposal devices are included within the Mitosol® (mitomycin for solution) Kit for Ophthalmic Use.


Special Purchasing Instructions: How to Purchase

MOXEZA (moxifloxacin hydrochloride (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerococcus viridans*; Corynebacterium macginleyi*; Enterococcus faecalis*; Micrococcus luteus*; Staphylococcus arlettae*; Staphylococcus aureus; Staphylococcus capitis; Staphylococcus epidermidis; Staphylococcus haemolyticus; Staphylococcus hominis; Staphylococcus saprophyticus*; Staphylococcus warneri*; Streptococcus mitis*; Streptococcus pneumoniae; Streptococcus parasanguinis*; Escherichia coli*; Haemophilus influenzae; Klebsiella pneumoniae*; Propionibacterium acnes; Chlamydia trachomatis*.

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

Bacterial conjunctivitis caused by susceptible strains of listed organisms:

  • Instill 1 drop in the affected eye(s) 2 times daily for 7 days.

►Recurrent corneal erosion:

  • Follow normal dosing patterns.

How Supplied:  
  • 3 mL bottles

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 36˚ – 77˚F (2˚ – 25˚C).


MOXIFLOXACIN (moxifloxacin (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*; Micrococcus luteus*;Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus haemolyticus; Staphylococcus hominis; Staphylococcus warneri*; Streptococcus pneumoniae; Streptococcus viridans group; Acinetobacter lwoffii*; Haemophilus influenzae; Haemophilus parainfluenzae*; Chlamydia trachomatis.

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

Bacterial conjunctivitis caused by susceptible strains of the listed organisms:

  • Instill 1 drop in the affected eye 3 times a day for 7 days.
  • For topical ophthalmic use.

►Recurrent corneal erosion:

  • Follow normal dosing patterns.

How Supplied:  
  • 3 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36˚ – 77˚F (2˚ – 25˚C).


MURO 128 (sodium chloride (5%) hypertonicity ophthalmic ointment; (2%; 5%) ophthalmic solution)
Over the Counter
Topical
Ointment
Ophthalmic Solution
Hyperosmotic Medications
Indications/Usage:

Used for the temporary relief of corneal edema.


Typical Dosing:  

Corneal edema:

  • Ophthalmic ointment:
    • Pull down the lower lid of affected eye and apply a small amount (¼ inch) of ointment to the inside of eyelid every 3 – 4 hours or as needed.
  • Ophthalmic solution:
    • Instill 1 – 2 drops in the affected eye(s) every 3 – 4 hours or as needed.

Recurrent corneal erosion, chronic:

  • Ophthalmic ointment:
    • Pull down the lower lid of affected eye and apply a small amount (¼ inch) of ointment to the inside of eyelid every night at bedtime.
    • Continue treatment for 3 – 6 months.
  • Ophthalmic solution:
    • Instill 1 – 2 drops in the affected eye(s) 4 times daily.
    • Continue treatment for 3 – 6 months.
Recurrent corneal erosion typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 5% Ophthalmic ointment:
    • 3.5 g tubes
  • 5% Ophthalmic solution:
    • 15 mL bottles
    • 30 mL bottles
  • 2% Ophthalmic solution:
    • 15 mL bottles

Preservatives:  

None listed in package insert (ophthalmic ointment); polyparaben, methylparaben (ophthalmic solution)


Storage:  
  • Ophthalmic ointment:
    • Store at 59° – 77°F (15° – 25°C).
    • Keep tightly closed.
    • Do not freeze.
    • See crimp of tube or carton for Lot Number and Expiration Date.
    • Do not use if difficult to dispense or visible particles are seen in the product.
  • Ophthalmic solution:
    • Store upright at 59° – 77°F (15° – 25°C).
    • Keep tightly closed.


MYDRIACYL (tropicamide (0.5%; 1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegics
Indications/Usage:

Indicated for mydriasis and cycloplegia for diagnostic procedures.


Typical Dosing:  

►Mydriasis and cycloplegia for diagnostic procedures: 

►Refraction: 

  • Instill 1 – 2 drops of 1% solution in the eye(s), repeated in 5 minutes. If patient is not seen within 20 – 30 minutes, an additional drop may be instilled to prolong mydriatic effect.
  • Individuals with heavily pigmented irides may require higher strength or more doses.
  • Mydriasis will reverse spontaneously with time, typically in 4 – 8 hours. However, in some cases, complete recovery may take up to 24 hours.

►Examination of fundus:

  • Instill 1 – 2 drops of 0.5% solution 15 – 20 minutes prior to examination.
  • Individuals with heavily pigmented irides may require higher strength or more doses.
  • Mydriasis will reverse spontaneously with time, typically in 4 – 8 hours. However, in some cases, complete recovery may take up to 24 hours.

How Supplied:  
  • 0.5% ophthalmic solution
    • 15 mL bottles
  • 1% ophthalmic solution
    • 2 mL bottles
    • 3 mL bottles
    • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 46°– 80°F (8° – 27°C).
  • Do not refrigerate or store at high temperatures. 
  • Keep container tightly closed.


NAPHCON-A (pheniramine maleate (0.3%) – naphazoline hydrochloride (0.025%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Ocular Decongestants/Vasoconstrictors
Indications/Usage:

Used for the temporary relief of redness and itching of the eye(s) due to: ragweed, pollen, grass, animal dander and hair.


Typical Dosing:  

►Redness and itching of the eyes:

  • Adults and children 6 years and over: 
    • Put 1 – 2 drops in the affected eye(s) up to 4 times daily.
  • Children under 6 years:
    • Ask a doctor.

How Supplied:  
  • 5 mL bottles
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Protect from light.


231 items found